Pneumotox » Drug » PD-1/PD-L1-inhibitors or blocking agents/drugs

PD-1/PD-L1-inhibitors or blocking agents/drugs

5

Adverse effects may indicate drug efficacy. Therefore, discontinuation should be discussed carefully. As has reinstitution of treatment. For review of pulmonary and nonpulmonary AEs, see under PMID�26371282,�27532025. Guidelines are available at manufacturers' websites

Last update : 04/11/2017

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

2

I.b Pneumonitis (ILD)

3

II.b ARDS - Acute lung injury

1

IV.d Cough (lone)

1

XII.ai Cardiotoxicity

1

XV.a Path: NSIP-cellular pattern (see also Ia, Ib)

1

XV.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

1

XV.c Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

1

XV.e Path: ILD with a granulomatous component (see also Im)

1

Diagnosing DIRD

1

Drug and radiation history

2

Drug singularity - Correct identification of the drug

3

Consistent timing of exposure v. onset of symptoms

4

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

5

Careful exlusion of another cause

6

Remission of symptoms with removal of drug

7

Recurrence with rechallenge (rarely advisable)

8

Causality assessment

More detailed checklist